 Connection
Larry Moreland to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Larry Moreland has written about Randomized Controlled Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.446 |
|
|
|
-
Krischer J, Cronholm PF, Burroughs C, McAlear CA, Borchin R, Easley E, Davis T, Kullman J, Carette S, Khalidi N, Koening C, Langford CA, Monach P, Moreland L, Pagnoux C, Specks U, Sreih AG, Ytterberg S, Merkel PA. Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. J Med Internet Res. 2017 02 28; 19(2):e50.
Score: 0.083
-
Pagnoux C, Carette S, Khalidi NA, Walsh M, Hiemstra TF, Cuthbertson D, Langford C, Hoffman G, Koening CL, Monach PA, Moreland L, Mouthon L, Seo P, Specks U, Ytterberg S, Westman K, Hoglund P, Harper L, Flossman O, Luqmani R, Savage CO, Rasmussen N, de Groot K, Tesar V, Jayne D, Merkel PA, Guillevin L. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol. 2015 Mar-Apr; 33(2 Suppl 89):S-77-83.
Score: 0.073
-
Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006 03; 5(3):185-6.
Score: 0.039
-
Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005 Sep; 5(9):1245-54.
Score: 0.037
-
Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, Hugenberg ST, Manzi S, Moreland LW, Oddis CV, Schnitzer TJ, Sharma L, Wolfe F, Yocum DE. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum. 2004 Dec 15; 51(6):933-40.
Score: 0.036
-
Cronholm PF, Applequist J, Krischer J, Fontenot E, Davis T, Burroughs C, McAlear CA, Borchin R, Kullman J, Carette S, Khalidi N, Koening C, Langford CA, Monach P, Moreland L, Pagnoux C, Specks U, Sreih AG, Ytterberg SR, Merkel PA. A study of implementation factors for a novel approach to clinical trials: constructs for consideration in the coordination of direct-to-patient online-based medical research. BMC Med Res Methodol. 2024 Oct 18; 24(1):244.
Score: 0.035
-
Baker JF, ODell JR, England BR, Giles JT, Newcomb JA, George MD, Thiele G, Moreland L, Bridges SL, Curtis JR, Mikuls TR. Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Ann Rheum Dis. 2024 Mar 12; 83(4):429-436.
Score: 0.034
-
Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics. 2004; 22(2 Suppl 1):39-53.
Score: 0.033
-
Moreland LW. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. Isr Med Assoc J. 2001 Sep; 3(9):686-90.
Score: 0.028
-
Aslibekyan S, Brown EE, Reynolds RJ, Redden DT, Morgan S, Baggott JE, Sha J, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Bridges SL, Arnett DK. Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. Pharmacogenomics J. 2014 Feb; 14(1):48-53.
Score: 0.016
-
Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging. 2006; 23(2):167-78.
Score: 0.010
-
Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003 Apr; 30(4):691-6.
Score: 0.008
-
Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 Jun; 46(6):1460-9.
Score: 0.007
-
Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology (Oxford). 2001 Jun; 40(6):615-22.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|